$HIMS News

HIMS Stock On A 3-Day Slide: CFO Cashes Out $229K In Shares Ahead Of FDA Peptide Meeting

Hims & Hers Chief Accounting Officer, Irene Becklund, Announces Departure from the Company

3 Reasons HIMS Has Explosive Upside Potential

Hims & Hers to Announce Second Quarter 2026 Financial Results on August 10, 2026

Is Most-Watched Stock Hims & Hers Health, Inc. (HIMS) Worth Betting on Now?

HIMS Stock Logs Worst Week In 2 Months — Turns To Peptides Campaign Ahead Of Key FDA Meeting

B of A Securities Maintains Neutral on Hims & Hers Health, Raises Price Target to $37

Hims & Hers Health: The Market Still Doesn't Get It

Here's Why Hims & Hers Health, Inc. (HIMS) Fell More Than Broader Market

Hims & Hers (HIMS) Stock May Be Undervalued After FDA Peptide Questions

Hims & Hers Health vs. Teladoc Health: Which Healthcare Stock Is a Better Buy in 2026?

HIMS Stock Rises Overnight: CEO Shrugs Off Wild Swings, Bets On ‘Gold Standard’ Of Healthcare Over Next Decade

HIMS Stock Hits 2026 High After Unlocking $400M Working Capital Through JPMorgan — Retail Gets Less Bearish

Here’s How Much You Would Have Made Owning Hims & Hers Health Stock In The Last 5 Years

Hims & Hers Stock Surges as Analysts Lift Price Targets

Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know

Hims & Hers Health’s Peptide Opportunity Tempered By FDA Recommendation, Says Analyst

Canaccord Genuity Maintains Buy on Hims & Hers Health, Raises Price Target to $40

B of A Securities Maintains Neutral on Hims & Hers Health, Raises Price Target to $36

HIMS Stock Slips Overnight After FDA Staff Questions Safety Of Popular Peptides — But One Analyst Says ‘This Isn’t The End’